

# **Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/P14B8F908A6FEN.html>

Date: October 2022

Pages: 138

Price: US\$ 2,000.00 (Single User License)

ID: P14B8F908A6FEN

## **Abstracts**

Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs In Development, 2022, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 2, 21, 17, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 6, 1 and 1 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).

The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction  
Global Markets Direct Report Coverage  
Pontine Glioma - Overview  
Pontine Glioma - Therapeutics Development  
Pipeline Overview  
Pipeline by Companies  
Pipeline by Universities/Institutes  
Products under Development by Companies  
Products under Development by Universities/Institutes  
Pontine Glioma - Therapeutics Assessment  
Assessment by Target  
Assessment by Mechanism of Action  
Assessment by Route of Administration  
Assessment by Molecule Type  
Pontine Glioma - Companies Involved in Therapeutics Development  
Pontine Glioma - Drug Profiles

### **8H-9 - DRUG PROFILE**

Product Description  
Mechanism Of Action  
abemaciclib - Drug Profile  
Product Description  
Mechanism Of Action  
ACT-001 - Drug Profile  
Product Description  
Mechanism Of Action  
Alocelyvir - Drug Profile  
Product Description  
Mechanism Of Action  
AMXT-1501 + eflornithine hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
BXQ-350 - Drug Profile  
Product Description  
Mechanism Of Action  
Cabometyx - Drug Profile

Product Description

Mechanism Of Action

CBL-0137 - Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Diffuse Intrinsic Pontine Glioma and Glioblastoma - Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

cemiplimab - Drug Profile

Product Description

Mechanism Of Action

cobimetinib fumarate - Drug Profile

Product Description

Mechanism Of Action

disufenton sodium - Drug Profile

Product Description

Mechanism Of Action

doxorubicin - Drug Profile

Product Description

Mechanism Of Action

ensartinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

everolimus - Drug Profile

Product Description

Mechanism Of Action

fimepinostat - Drug Profile

Product Description

Mechanism Of Action

G2B-001 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Diffuse Intrinsic Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target B7H3 for CNS Tumor - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target GD-2 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

indoximod - Drug Profile

Product Description

Mechanism Of Action

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

Kid EDV - Drug Profile

Product Description

Mechanism Of Action

larotrectinib sulfate - Drug Profile

Product Description

Mechanism Of Action

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

MANA-677679 - Drug Profile

Product Description

Mechanism Of Action

marizomib - Drug Profile

Product Description

Mechanism Of Action

MDNA-55 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

nimotuzumab - Drug Profile

Product Description

Mechanism Of Action

nivolumab - Drug Profile

Product Description

Mechanism Of Action

omburtamab - Drug Profile

Product Description

Mechanism Of Action

ONC-201 - Drug Profile

Product Description

Mechanism Of Action

ORX-101 - Drug Profile

Product Description

Mechanism Of Action

P-28 - Drug Profile

Product Description

Mechanism Of Action

palbociclib - Drug Profile

Product Description

Mechanism Of Action

panobinostat - Drug Profile

Product Description

Mechanism Of Action

panobinostat SR - Drug Profile

Product Description

Mechanism Of Action

paxalisib - Drug Profile

Product Description

Mechanism Of Action

pomalidomide - Drug Profile

Product Description

Mechanism Of Action

RG-2833 - Drug Profile



Product Description  
Mechanism Of Action  
ribociclib succinate - Drug Profile  
Product Description  
Mechanism Of Action  
RNL - Drug Profile  
Product Description  
Mechanism Of Action  
S-588410 - Drug Profile  
Product Description  
Mechanism Of Action  
selinexor - Drug Profile  
Product Description  
Mechanism Of Action  
SL-701 - Drug Profile  
Product Description  
Mechanism Of Action  
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile  
Product Description  
Mechanism Of Action  
sotigalimab - Drug Profile  
Product Description  
Mechanism Of Action  
SurVaxM - Drug Profile  
Product Description  
Mechanism Of Action  
tasadenoturev - Drug Profile  
Product Description  
Mechanism Of Action  
trabedersen - Drug Profile  
Product Description  
Mechanism Of Action  
unesbulin - Drug Profile  
Product Description  
Mechanism Of Action  
Vaccine for Glioma - Drug Profile  
Product Description  
Mechanism Of Action

Vaccine for Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile

Product Description

Mechanism Of Action

WP-1066 - Drug Profile

Product Description

Mechanism Of Action

zotiraciclib citrate - Drug Profile

Product Description

Mechanism Of Action

Pontine Glioma - Dormant Projects

Pontine Glioma - Discontinued Products

Pontine Glioma - Product Development Milestones

Featured News & Press Releases

Nov 20, 2022: Oncotelic presenting data for OT101 against diffuse intrinsic pontine glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

Oct 06, 2022: PNOC clinical study of kazia's paxalisib in childhood brain cancer expands internationally

Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma

Jun 15, 2022: Midatech Pharma : An update to MTX110 study in pediatric patients with DIPG to be presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)

Nov 22, 2021: DNATRIX announces oral presentation of positive overall survival data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) annual meeting

Aug 13, 2021: Plus Therapeutics to present data from ReSPECT-GBM trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting

Jul 19, 2021: Oblato announces that it has received a positive response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an expanded access program

Jul 07, 2021: The new immunomodulator ACT001 shows great potential

Apr 29, 2021: Y-mAbs announces Omburtamab data to be presented at 2021 ASCO annual meeting

Mar 25, 2021: Midatech Pharma announces MTX110 update & headline results for 2020

Mar 03, 2021: Oblato announces Fast Track Designation of OKN-007 for diffuse intrinsic pontine glioma from the FDA

Dec 11, 2020: Midatech Pharma announces MTX110 Ppogrammes to be presented at ISPNO 2020

Dec 10, 2020: Oblato announces discussion outcome with FDA for development of OKN-007 for diffuse intrinsic pontine glioma

Dec 10, 2020: Kazia to collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for new Paxalisib combination study in DIPG

Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Pontine Glioma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pontine Glioma - Dormant Projects, 2022

Pontine Glioma - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Pontine Glioma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P14B8F908A6FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P14B8F908A6FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

